# US 2014/0154277 A1 · Pharmaceutical Compositions Comprising Soluble CD137

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2014/0154277 A1
- Document ID: US20140154277A1
- Status: Published application
- Kind: A1
- Application number: 14/161,150
- Filed: 2014-01-22
- Published: 2014-06-05
- Earliest claimed: 2011-10-19
- Assignees: University of Cincinnati
- Applicants: University of Cincinnati
- Inventors: William Ridgway; David Erwin Adams; Kritika Kachapati
- Web page: https://patentgrep.com/patent/US20140154277A1

## CPC

- A61K 38/177: {Receptors; Cell surface antigens; Cell surface determinants}
- A61K 38/1793: {for cytokines; for lymphokines; for interferons}
- A61K 40/11: T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A61K 40/22: Immunosuppressive or immunotolerising
- A61K 40/416: {Antigens related to auto-immune diseases; Preparations to induce self-tolerance}
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 17/06: Antipsoriatics
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- C12N 5/0637: {Immunosuppressive T lymphocytes, e.g. regulatory T cells or Treg}
- C12N 2501/599: with CD designations not provided for elsewhere
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

A method for treating or preventing a T-cell-mediated autoimmune disease is provided herein, the method including administering to a mammal in need thereof a therapeutically effective amount of soluble CD137 or CD137pos regulatory T cells. Also provided are pharmaceutical compositions for treating or preventing T-cell-mediated autoimmune diseases, the pharmaceutical compositions including a therapeutically effective amount of soluble CD137 or CD137pos regulatory T cells and a pharmaceutically-acceptable carrier.

## Claims

### Claim at position 1

1-12. (canceled)

### Claim 13

A pharmaceutical composition for the treatment of a T-cell-mediated autoimmune disease comprising:
a therapeutically effective amount of soluble CD137; and
a pharmaceutically-acceptable carrier.

### Claim 14 (depends on 13)

The pharmaceutical composition of claim 13, wherein the pharmaceutical composition is in the form of an injectable suspension.

### Claim 15 (depends on 13)

The pharmaceutical composition of claim 13, wherein the pharmaceutical composition is administered intravenously.

### Claim 16 (depends on 13)

The pharmaceutical composition of claim 13, wherein the T-cell-mediated autoimmune disease is selected from the group consisting of type 1 diabetes, multiple sclerosis, psoriasis, and rheumatoid arthritis.

### Claim at position 6

17-20. (canceled)
